Curi Bio Publicizes Mantarray™ Platform for Evaluation

Curi Bio, a number one developer of human stem cell-based platforms for drug discovery, in the present day introduced the Mantarray™ platform for human-relevant 3D engineered muscle tissue (EMT) evaluation.

Curi’s Mantarray platform allows the invention, security, and efficacy testing of latest therapeutics by offering parallel evaluation of 3D EMTs with grownup human-like practical profiles. By offering drug builders human-relevant tissue-specific biosystems within the preclinical stage of drug improvement, Curi goals to assist pharmaceutical companions develop safer and simpler therapeutics in much less time, at a decrease price. Curi Bio is presently partnering with a number of main pharmaceutical firms to speed up the event of the Mantarray platform and to use it to drug discovery and improvement initiatives.

Cardiovascular illnesses usually contain a gradual lack of cardiac contractile energy and performance, finally resulting in coronary heart failure. Cardiomyocytes derived from human induced pluripotent stem cells (iPSC-CMs) supply a promising path to mannequin the contractile deficiencies seen within the hearts of sufferers with cardiovascular illnesses.

Nevertheless, 2D cell fashions lack the physiologically related construction and performance of 3D fashions. Consequently, 3D engineered muscle tissues have been rising in use within the drug improvement business. But current 3D EMT options are complicated and low throughput, usually counting on laborious serial optical imaging of every tissue to measure contractility.

Curi will make the Mantarray platform out there to pharmaceutical and analysis clients as a standalone bioscience instrument along with multiwell consumable plates for casting and assaying EMTs. Curi may even supply service contracts and partnerships leveraging the Mantarray know-how for purposes in drug discovery, illness modeling, and security and efficacy screening.

Curi’s Mantarray platform leverages a proprietary, label-free, non-optical, electromagnetic measurement system for direct contractility evaluation of as much as 24 parallel iPSC-derived 3D engineered muscle tissues concurrently.

With the Mantarray platform, scientists can obtain clinically related practical measurements of human iPSC-derived engineered muscle tissue contractility, with a throughput and reproducibility appropriate with higher-throughput screening workflows. Mantarray brings clinically related practical information into the earliest phases of preclinical testing of latest medicines.

Leveraging human iPSC-derived cells, Mantarray 3D tissues can be utilized to create high-fidelity fashions of human illnesses. For instance, Mantarray 3D EMTs could be gene-edited with a CRISPR/Cas9 system to mannequin human illnesses akin to Duchenne muscular dystrophy and varied cardiomyopathies. Multi-modal Mantarray information present enhanced illness stratification offering researchers with extra physiological information for the invention and validation of latest therapeutics.

The Mantarray platform additionally gives a breakthrough cardiotoxicity security and efficacy testing platform with novel magnetic detection of drug-induced contractile adjustments. The magnetic detection strategy can measure each acute and persistent drug responses.

Medicine could be measured on the order of seconds to minutes with sufficient sensitivity to measure dose-response-like conduct. Alternatively, longer-term persistent experiments could be carried out over the course of days. Purposes embody acute and persistent structural cardiotoxicity analysis.

“At Curi Bio, our objective is to supply researchers with modern human-relevant cells, programs, and information to speed up the invention of latest medicines,” mentioned Curi CEO Michael Cho.

By offering drug builders unprecedented entry to clinically-relevant preclinical fashions that extra intently recapitulate human cardiac and skeletal muscle tissue, Curi is closing the hole between preclinical outcomes and medical impression.”

Dr. Nicholas Geisse, Chief Science Officer of Curi Bio, will current Curi’s Mantarray platform and Curi’s lately introduced ComboMat platform in a presentation on the Discovery on Goal 2020 Digital Convention.

Occasion: Discovery on Goal 2020

Date: Thursday, September 17, 2020

Time: 11:15 AM EDT

Session: Illness Modeling

Title: Structural Maturation within the Improvement of hiPSC-Cardiomyocyte Fashions for Preclinical Security, Efficacy, and Discovery

Curi’s Mantarray platform integrates proprietary strategies and IP solely licensed to Curi Bio by the College of Washington.

To study extra about how the Mantarray platform can enhance the predictive energy of 3D EMTs, or about Curi’s different human-relevant preclinical platform applied sciences and providers, please attain out at



Supply hyperlink

Leave a Reply

Your email address will not be published. Required fields are marked *